Neuromyelitis Optica

• EMA approval · 2026-08-21
  EMA Authorised: Enspryng (satralizumab) — Roche Registration GmbH

  Authorised market approval of Enspryng (satralizumab) by Roche Registration GmbH for neuromyelitis optica in the European Union.

• EMA approval · 2026-02-17
  EMA Authorised: Uplizna (inebilizumab) — Amgen Europe B.V.

  The European Medicines Agency has authorised Uplizna (inebilizumab) for the treatment of Neuromyelitis Optica in adults.